MGTX — MeiraGTx Holdings plc

Nasdaq · Health Care · Biotechnology · CIK 1735438 ·
Last close
$9.60
Market Cap
$889.05M
52W High
$11.85
52W Low
$6.62
ADV30
949,600
Next earnings
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 293,000 95,000 -40,817,000 -46,313,000 244,655,000 71,541,000 302,785,000
Dec 2025 75,364,000 74,888,000 26,472,000 15,088,000 244,430,000 65,931,000 250,223,000
Sep 2025 410,000 97,000 -46,051,000 -50,513,000 189,471,000 14,841,000 230,028,000
Jun 2025 3,691,000 1,015,000 -44,793,000 -38,795,000 198,716,000 32,166,000 195,756,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-46,295,000
Investing CF
$-4,107,000
Financing CF
$12,272,000
CapEx
$-4,236,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.16
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-816,223,000
Inventory
$0
Receivables
$18,286,000
ST Investments
EBIT TTM
$-102,004,000
Pretax Income TTM
$-114,201,000
Interest Exp TTM
$12,197,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$79,758,000
EBITDA
$-92,720,000
Free Cash Flow
$45,015,624
Enterprise Value
$871,703,936
Total Cash
$71,541,000
Total Debt
$87,533,000
Shares Out
92,609,516
Trailing EPS
$-1.48
Book Value
$-0.71
ROE
ROA
-28.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 81,391,000 -105,968,000 -114,201,000 244,430,000 250,223,000 -46,359,000
Dec 2024 33,279,000 -164,212,000 -147,791,000 269,751,000 201,924,000 -104,495,000
Dec 2023 14,017,000 -137,061,000 -84,027,000 326,744,000 188,567,000 -105,365,000
Dec 2022 15,920,000 -116,355,000 -129,615,000 318,237,000 200,499,000 -73,098,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.39

Peers — same industry

TickerNameMarket CapLastDaily %
SANA Sana Biotechnology, Inc. $848.79M $3.05
CGEM Cullinan Therapeutics, Inc. $950.14M $15.46
AURA Aura Biosciences, Inc. $786.77M $7.61
VOR Vor Biopharma Inc. $764.02M $14.10
ALVO Alvotech $1.07B $3.42

News headlines (Yahoo Finance, 1h cache)

Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint
2026-05-20 12:36 · Yahoo
Here's What Analysts Are Forecasting For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its First-Quarter Results
2026-05-17 13:55 · Yahoo
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-14 20:30 · Yahoo
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-14 13:10 · Yahoo
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
2026-05-14 12:00 · Yahoo
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
2026-05-07 14:00 · Yahoo
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
2026-05-07 13:02 · Yahoo
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 12:50 · Yahoo
Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know
2026-05-05 14:00 · Yahoo
Miami International, Nathan’s Famous, and 3 More Stocks See Action From Activist Investors
2026-05-01 22:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.